8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
People assigned to a diet, food or program and measured.
2018 / Randomized, double-blind, placebo-controlled pilot trial
Thirty-nine participants with mild to moderate Alzheimer's disease were randomized to receive either an oral preparation containing 5 mg resveratrol, 5 g dextrose, and 5 g malate (RGM) or a matching placebo twice daily with grape juice for 1 year. At 12 months, change scores on the ADAS-cog, MMSE, ADCS-ADL, and NPI showed less deterioration in the treatment group than the control group, but none of these differences reached statistical significance. The intervention was found to be safe and well tolerated, with the most common adverse events being falls (all in the control group and deemed unrelated to the study).
Zhu CW, Grossman H, Neugroschl J, et al. Alzheimers Dement (N Y), 2018. PMID 30480082
2017 / Randomized controlled trial
In a double-blind pilot study, 10 older adults with mild cognitive decline received an active grape formulation or placebo for six months. Participants taking the grape formulation maintained cerebral metabolism on FDG-PET scans, whereas the placebo group experienced significant metabolic declines in posterior cingulate and temporal regions (p < 0.05). Neuropsychological test scores did not differ significantly between groups.
Lee J, Torosyan N, Silverman DH Exp Gerontol, 2017. PMID 27856335
2017 / Randomized placebo-controlled trial
Eighty post-menopausal women aged 45-85 years were randomized to take trans-resveratrol or placebo for 14 weeks. Compared to placebo, resveratrol led to 17% increases in cerebrovascular responsiveness (CVR) to both hypercapnic (p = 0.010) and cognitive stimuli (p = 0.002). Resveratrol significantly improved performance in verbal memory tasks (p = 0.041) and overall cognitive performance (p = 0.020), which correlated with the increase in CVR (r = 0.327; p = 0.048). Mood tended to improve across multiple measures, but the changes were not statistically significant.
Evans HM, Howe PR, Wong RH Nutrients, 2017. PMID 28054939
2017 / Randomized controlled trial (retrospective subset analysis)
Banked CSF and plasma samples from a subset of 38 biomarker-confirmed Alzheimer's disease subjects randomized to resveratrol (up to 1 g orally twice daily) or placebo for 52 weeks were analyzed. At 52 weeks, resveratrol significantly reduced CSF MMP9 and increased MDC, IL-4, and FGF-2 compared to placebo, while increasing plasma MMP10 and decreasing IL-12P40, IL12P70, and RANTES from baseline. Resveratrol treatment attenuated declines in MMSE scores, ADCS-ADL scores, and CSF Aβ42 levels over 52 weeks, without altering tau levels.
Moussa C, Hebron M, Huang X, et al. J Neuroinflammation, 2017. PMID 28086917
2017 / 12-week, parallel-group, single-blind randomized controlled trial
In the 'SMILES' trial, 67 adults with moderate to severe depression were randomized to receive either 7 sessions of dietary support from a clinical dietician (n=33) or a social support control protocol (n=34) over 12 weeks. The dietary support group showed significantly greater improvement on the MADRS compared with the control group (t(60.7) = 4.38, p < 0.001, Cohen's d = -1.16). Remission (MADRS <10) was achieved by 32.3% (n=10) of the intervention group compared to 8.0% (n=2) of controls (p = 0.028), with a number needed to treat of 4.1 (95% CI 2.3-27.8).
Jacka FN, O'Neil A, Opie R, et al. BMC Med, 2017. PMID 28137247
2017 / Randomized controlled trial
A 14-day randomized controlled trial assigned 171 low-fruit-and-vegetable-consuming young adults to a diet-as-usual control, an ecological momentary intervention (text reminders plus vouchers), or a fruit and vegetable intervention (FVI) providing two additional daily servings of fresh produce. Only participants in the FVI condition exhibited improvements in psychological well-being, showing increases in vitality, flourishing, and motivation relative to the other groups. No changes were observed for depressive symptoms, anxiety, or positive and negative mood. These benefits were not mediated by vitamin C, carotenoids, or psychological expectancies.
Conner TS, Brookie KL, Carr AC, et al. PLoS One, 2017. PMID 28158239
2017 / Controlled pharmacokinetic and pharmacodynamic trial
Healthy adults were administered cannabis brownies containing 10, 25, or 50 mg THC, with whole blood, oral fluid, and pharmacodynamic outcomes tracked over 9 days. Mean Cmax for THC in whole blood was 1, 3.5, and 3.3 ng/mL for the 10, 25, and 50 mg doses, with detection windows ranging from 0 to 22 h in blood and 1.9 to 22 h in oral fluid. Subjective drug and cognitive performance effects were generally dose dependent, peaked at 1.5–3 h post-administration, and lasted 6–8 h. Whole blood cannabinoid concentrations significantly correlated with subjective effects, but correlations with cognitive performance or between oral fluid and pharmacodynamic outcomes were non-significant or not orderly by dose.
Vandrey R, Herrmann ES, Mitchell JM, et al. J Anal Toxicol, 2017. PMID 28158482
2017 / Counterbalanced crossover trial and randomized controlled trial
Two double-blind studies examined mood 2 hours after blueberry or placebo drinks. Study 1 enrolled 21 young adults aged 18-21 in a counterbalanced crossover design, while Study 2 randomized 50 children aged 7-10. In both cohorts, consuming the flavonoid-rich blueberry beverage significantly boosted positive affect based on a significant drink-by-session interaction. Neither study detected any changes in negative affect.
Khalid S, Barfoot KL, May G, et al. Nutrients, 2017. PMID 28230732
2017 / Randomized controlled trial
Healthy older adults were randomized to consume 30 mL of anthocyanin-rich blueberry concentrate (12 participants) or isoenergetic placebo (14 participants) over 12 weeks. Blueberry supplementation led to significant increases in brain activity relative to placebo within multiple regions including Brodmann areas 4/6/10/21/40/44/45, precuneus, anterior cingulate, and insula/thalamus (p < 0.001). Significant improvements in grey matter perfusion were observed in parietal (5.0 ± 1.8 vs -2.9 ± 2.4%, p = 0.013) and occipital (8.0 ± 2.6 vs -0.7 ± 3.2%, p = 0.031) lobes, alongside evidence suggesting improvement in working memory (p = 0.05).
Bowtell JL, Aboo-Bakkar Z, Conway ME, et al. Appl Physiol Nutr Metab, 2017. PMID 28249119
2017 / Randomized clinical trial transformed into a cohort study
The PREADViSE trial evaluated whether vitamin E, selenium, or their combination could prevent dementia in asymptomatic older men, starting as a randomized clinical trial and continuing as a cohort study. Across 7338 analyzed men, dementia incidence was 4.4% (325 cases) and did not differ among the study arms. Adjusted hazard ratios compared with placebo were 0.88 (95% CI, 0.64-1.20) for vitamin E, 0.83 (95% CI, 0.60-1.13) for selenium, and 1.00 (95% CI, 0.75-1.35) for the combination.
Kryscio RJ, Abner EL, Caban-Holt A, et al. JAMA Neurol, 2017. PMID 28319243
2017 / Randomized controlled trial
Twenty-six older adults with a mean age of 65.4 years participated in a six-week randomized trial combining exercise with beet root juice or a placebo. The beet root juice group showed significantly higher somatomotor community structure consistency (P = 0.007) and fewer secondary connections to the insular cortex (P = 0.017). Peak exercise capacity also showed a nonsignificant trend toward improvement.
Petrie M, Rejeski WJ, Basu S, et al. J Gerontol A Biol Sci Med Sci, 2017. PMID 28329785
2017 / Randomised controlled trial
In a randomised controlled trial, 86 patients were recruited to undergo five sessions of mindfulness meditation or five sessions of relaxation therapy for tinnitus management. Thirty-four patients in the mindfulness meditation group and 27 patients in the relaxation therapy group completed the study. Both groups experienced statistically significant improvements across all outcome measures except the health status indicator, with greater score changes observed in the mindfulness meditation group.
Arif M, Sadlier M, Rajenderkumar D, et al. J Laryngol Otol, 2017. PMID 28357966
2017 / Randomized controlled trial
Children and adolescents with intractable epilepsy were randomized to a ketogenic diet (KD) or care as usual (CAU) and followed for 16 months. In total, 58% of the KD group completed follow-up (11 dropped out). At 16 months, 35% of KD participants achieved a seizure reduction of ≥50% from baseline versus 18% in the CAU group, and 46.2% reported decreased worst seizure severity versus 32% in CAU. Mean per-patient costs were €61,019 in the KD group compared with €53,367 (extrapolated) in CAU, giving an ICER of €46,564 per responder. The KD group had significantly more gastrointestinal issues at 4 months but fewer at 16 months compared to CAU; cost per QALY ratios were inconclusive due to minimal QALY differences.
Wijnen BFM, de Kinderen RJA, Lambrechts DAJE, et al. Epilepsy Res, 2017. PMID 28364726
2017 / Randomized crossover trial
In a randomized, double-blind crossover study of 20 healthy young adults, consuming 230 ml of purple grape juice was evaluated after a 20-minute absorption period. Grape juice significantly improved reaction times on a composite attention measure (p = 0.047) and raised calm ratings (p = 0.046) compared with placebo. However, acute supplementation produced no significant effects on episodic or working memory measures.
Haskell-Ramsay CF, Stuart RC, Okello EJ, et al. Eur J Nutr, 2017. PMID 28429081
2017 / Prospective, randomized, double-blind, placebo-controlled study
A randomized, double-blind, placebo-controlled pilot study evaluated the efficacy and safety of ashwagandha root extract (300 mg twice daily) compared with placebo for eight weeks in 50 adults with mild cognitive impairment. Compared to placebo, the ashwagandha group demonstrated significant improvements in immediate and general memory across multiple Wechsler Memory Scale III subtest scores, including logical memory I (p = 0.007) and II (p = 0.006). Significant improvements were also observed in executive function, sustained attention, and information-processing speed as measured by the Eriksen Flanker task (p = 0.002), Wisconsin Card Sort test (p = 0.014), Trail-Making test part A (p = 0.006), and the Mackworth Clock test (p = 0.009).
Choudhary D, Bhattacharyya S, Bose S J Diet Suppl, 2017. PMID 28471731
2017 / Double-blind, randomized, controlled, crossover trial
Eighteen patients with advanced Parkinson disease received single doses of Mucuna pruriens (MP) powder (high-dose 17.5 mg/kg, low-dose 12.5 mg/kg, or 3.5 mg/kg with benserazide), dispersible levodopa with benserazide (LD+DDCI, 3.5 mg/kg), levodopa alone (17.5 mg/kg), or placebo in randomized order. Compared to LD+DDCI, low-dose MP produced similar motor response with fewer dyskinesias and adverse events. High-dose MP induced greater motor improvement at 90 and 180 minutes, longer ON duration, fewer dyskinesias, and fewer adverse events than LD+DDCI and levodopa alone, with no differences in cardiovascular response.
Cilia R, Laguna J, Cassani E, et al. Neurology, 2017. PMID 28679598
2017 / Double-masked, randomized, placebo-controlled trial
A total of 62 community-dwelling older adults were randomized to receive 12 mg of lutein and zeaxanthin (L+Z) or a placebo, with data from 51 participants analyzed. Participants receiving L+Z had significant increases in MPOD (p < 0.03) and improvements in complex attention (p < 0.02) and cognitive flexibility (p < 0.04) compared to placebo. A trend was observed for executive function (p = 0.073), and composite memory improved specifically among male participants (p = 0.04).
Hammond BR, Miller LS, Bello MO, et al. Front Aging Neurosci, 2017. PMID 28824416
2017 / Randomized controlled trial
In a six-month randomized trial, 40 healthy adults ate one avocado daily or a control food providing no lutein. Avocado consumption increased serum lutein by 25% (p = 0.001) and raised macular pigment density from baseline (p = 0.001), whereas the control showed no pigment change. Memory improved in both groups, but sustained attention improved only with avocado intake (p = 0.033).
Scott TM, Rasmussen HM, Chen O, et al. Nutrients, 2017. PMID 28832514
2017 / Experimental intervention study with sham control
Seventeen healthy adults underwent 5-14 days of actigraphy followed by slow wave activity disruption during polysomnogram, compared to an identical sham protocol, with cerebrospinal fluid collected the following morning. Specific disruption of slow wave activity correlated with an increase in amyloid-β40 (r = 0.610, P = 0.009), an effect not observed for sleep duration, sleep efficiency, total protein, tau, YKL-40, or hypocretin. In addition, worse home sleep quality measured by actigraphy over the preceding six nights was associated with higher tau levels (r = 0.543, P = 0.045).
Ju YS, Ooms SJ, Sutphen C, et al. Brain, 2017. PMID 28899014
2017 / Randomized controlled trial
A randomized trial assigned 121 individuals with Parkinson disease to 200 mg of caffeine twice daily or placebo for 6 to 18 months. Caffeine did not change motor scores at six months compared to placebo (-0.48 points, 95% CI -3.21 to 2.25 on MDS-UPDRS-III). Participants receiving caffeine experienced a slight increase in dyskinesia and worse cognitive scores (0.66 points worse on Montreal Cognitive Assessment, 95% CI 0.01 to 1.32).
Postuma RB, Anang J, Pelletier A, et al. Neurology, 2017. PMID 28954882
2017 / Randomized clinical trial
Seventy patients with tinnitus were randomly divided into two groups receiving either melatonin (3 mg once daily) or sertraline (50 mg once daily) for 3 months. Baseline mean THI scores were 45.02 ± 17.67 for melatonin and 44.85 ± 20.57 for sertraline (P = 0.23). After 3 months, THI scores decreased significantly in both groups to 30.29 ± 19.62 and 36.96 ± 25.03, respectively (P < 0.01 for both), with a significantly greater decline observed in the melatonin group (P = 0.02).
Abtahi SH, Hashemi SM, Mahmoodi M, et al. Int J Prev Med, 2017. PMID 28966750
2017 / Randomized double-blind placebo-controlled trial
Fifty-one healthy young adults were randomized to receive daily lutein and zeaxanthin (n = 37) or placebo (n = 14) for one year. Supplementation significantly increased macular pigment optical density relative to placebo (p < 0.001). Furthermore, the active group exhibited notable gains in spatial recall (p < 0.04), reasoning capabilities (p < 0.05), and attention tasks (p < 0.04) beyond expected practice effects.
Renzi-Hammond LM, Bovier ER, Fletcher LM, et al. Nutrients, 2017. PMID 29135938
2017 / Randomized crossover trial
Forty healthy older adults aged 50 to 70 consumed a mixed berry beverage or a matched control beverage daily for five weeks in a randomized crossover trial. The berry drink reduced total and LDL cholesterol compared to baseline (P < 0.05) and compared to control (P < 0.005 and P < 0.01). Working memory performance improved after the berry beverage compared to control (P < 0.05), but other cardiometabolic variables remained unchanged.
Nilsson A, Salo I, Plaza M, et al. PLoS One, 2017. PMID 29141041
2017 / Randomized controlled trial
In a randomized trial, 142 graduate students were administered a single 1,000 mg dose of ascorbic acid or placebo. Overall, no significant changes from baseline were observed in state-anxiety or visual analogue mood scores. However, among the 25% most anxious participants (37 women), ascorbic acid produced a significant reduction from baseline in state-anxiety and mood-scale anxiety subscale scores.
Moritz B, Schwarzbold ML, Guarnieri R, et al. Acta Neurobiol Exp (Wars), 2017. PMID 29369301